Cognitive dysfunction in major depressive disorder: Effects on psychosocial functioning and implications for treatment

Canadian Journal of Psychiatry

Volumn 59, Issue 12, 2014, Pages 649-654

  Lam, Raymond W ^a   Kennedy, Sidney H ^b   McIntyre, Roger S ^b   Khullar, Atul ^c  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Antidepressants; Cognitive dysfunction; Depression; Psychosocial functioning

Indexed keywords

ANTIDEPRESSANT AGENT;

ANTIDEPRESSANT ACTIVITY; CLINICAL ASSESSMENT; CLINICAL EFFECTIVENESS; COGNITIVE DEFECT; DISEASE ASSOCIATION; EVIDENCE BASED PRACTICE; HUMAN; MAJOR DEPRESSION; PSYCHIATRIC TREATMENT; PSYCHOPHARMACOTHERAPY; PSYCHOTHERAPY; REVIEW; SOCIAL COGNITION; SOCIAL PSYCHOLOGY; TREATMENT INDICATION; COGNITION DISORDERS; COMORBIDITY; DEPRESSIVE DISORDER, MAJOR; HUMAN RELATION;

COGNITION DISORDERS; COMORBIDITY; DEPRESSIVE DISORDER, MAJOR; HUMANS; INTERPERSONAL RELATIONS;

EID: 84919456307     PISSN: 07067437     EISSN: 14970015     Source Type: Journal    
DOI: 10.1177/070674371405901206     Document Type: Review

References (39)

1. Gilmour H, Patten SB. Depression and work impairment. Health Rep. 2007;18:9-22.
2. Ferrari AJ, Charlson FJ, Norman RE, et al. Burden of depressive disorders by country, sex, age, and year: findings from the global burden of disease study 2010. PLoS Med. 2013;10:e1001547.
3. Lam RW, Filteau MJ, Milev R. Clinical effectiveness: the importance of psychosocial functioning outcomes. J Affect Disord. 2011;132(Suppl 1):S9-S13.
4. Greer TL, Kurian BT, Trivedi MH. Defining and measuring functional recovery from depression. CNS Drugs. 2010;24:267-284.
5. Zimmerman M, McGlinchey JB, Posternak MA, et a l. Discordance between self-reported symptom severity and psychosocial functioning ratings in depressed outpatients: implications for how remission from depression should be defined. Psychiatry Res. 2006;141:185-191.
6. McIntyre RS, Cha DS, Soczynska JK, et al. Cognitive deficits and functional outcomes in major depressive disorder: determinants, substrates, and treatment interventions. Depress Anxiety. 2013;30:515 -527.
7. Murrough JW, Iacoviello B, Neumeister A, et al. Cognitive dysfunction in depression: neurocircuitry and new therapeutic strategies. Neurobiol Learn Mem. 2011;96:553-563.
8. Hasselbalch BJ, Knorr U, Hasselbalch SG, et al. Cognitive deficits in the remitted state of unipolar depressive disorder. Neuropsychology. 2012;26:642-651.
9. Chamberlain SR, Saha kian BJ. The neuropsychology of mood disorders. Curr Psychiatry Rep. 2006;8:458-463.
10. Conradi HJ, Ormel J, de Jonge P. Presence of individual (residual) symptoms during depressive episodes an d periods of remission: a 3-year prospective study. Psychol Med. 2011;41:1165-1174.
11. Baune BT, Miller R, McAfoose J, et al. The role of cognitive impairment in general functioning in major depression. Psychiatry Res. 2010;176:183-189.
12. Halvorsen M, Hoifodt RS, Myrbakk IN, et al. Cognitive function in unipolar major depression: a comparison of currently depressed, previously depre ssed, and never depressed individuals. J Clin Exp Neuropsychol. 2012;34:782-790.
13. Snyder HR. Major depressive disorder is associated with broad impairments on neuropsychological measures of executive fun ction: a meta-analysis and review. Psychol Bull. 2013;130:81-132.
14. Hasselbalch BJ,Knorr U,Kessing LV., Cognitive impairment in the remitted state of unipolar depressive disorder: a systematic review, J Affect Disord, 2011, 134, 20-31.
15. Disner SG, Beevers CG, Haigh EA, et al. Neural mechanisms of the cognitive model of depression. Nat Rev Neurosci. 2011;12:467-477.
16. Withall A, Harris LM, Cumming SR. A longitudinal study of cognitive function in melancholic and non-melancholic subtypes of major depressive disorder. J Affect Disord. 2010;123:150-157.
17. Jaeger J, Berns S, Uzelac S, et al. Neurocognitive deficits and disability in major depressive disorder. Psychiatry Res. 2006;145:39-48.
18. Naismith SL, Longley WA, Scott EM, et al. Disability in major depression related to self-rated and objectively-measured cognitive deficits: a preliminary study. BMC Psychiatry. 2007;7:32-38.
19. Antikainen R, Hä nninen T, Honkalampi K, et al. Mood improvement reduces memory complaints in depressed patients. Eur Arch Psychiatry Clin Neurosci. 2001;251:6-11.
20. Hasselbalch BJ, Knorr U, Hasselbalch SG, et al. The cumulative load of depressive illness is associated with cognitive function in the remitted state of unipolar depressive disorder. Eur Psychiatry. 2013; 28:349-355.
21. Evans VC, Chan SS, Iverson GL, et al. Systematic review of neurocognition and occupational functioning in major depressive disorder. Neuropsychiatry. 2013;3:97-105.
22. Evans VC, Iverson GL, Yatham LN, et al. The relationship between neurocognitive and psychosocial functioning in major depressive disorder: a systematic review. J Clin Psychiatry. Forthcoming.
23. . Buist-Bouwman MA, Ormel J, de Graaf R, et al. Mediators of the association between depression and role functioning. Acta Psychiatr Scand. 2008;188:451-458.
24. Herrera-Guzman I, Gudayol -Ferré E, Herrera-Guzman D, et al. Effects of selective serotonin reuptake and dual serotonergicnoradrenergic reuptake treatments on memory and mental processing speed in patients with major depressive disorder. J Psychiatry Res. 200 9;43:855-863.
25. Fava M, Graves LM, Benazzi F, et al. A cross-sectional study of the prevalence of cognitive and physical symptoms during long-term treatment. J Clin Psychiatry. 2006;67:1754-1759.
26. Nuechterline KH, Green MF, Kern RS, et al. The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity. Am J Psychiatry. 2008;165:203-213.
27. Yatham LN, Torres IJ, Malhi GS, et al. The International Society for Bipolar Disorders-Battery for Assessment of Neurocognition (ISBD-BANC). Bipolar Disord. 2010;12:351-363.
28. Walker MP. Cognitive consequences of sleep and sleep loss. Sleep Med. 2008;9(Suppl 1):S29-S34.
29. Durmer JS, Dinges DF. Neurocognitive consequences of sleep deprivation. Semin Neurol. 2005;25:117-129.
30. Wagner S, Doering B, Helmreich I, et al. A meta-analysis of executive dysfunctions in unipolar major depressive disorder without psychotic symptoms and their changes during antidepres sant treatment. Acta Psychiatr Scand. 2012;125:281-292.
31. McLennan SN, Mathias JL. The depression-executive dysfunction (DED) syndrome and response to antidepressants: a meta-analytic review. Int J Geriatr Psychiatry. 2010;25:933-944.
32. Herrera-Guzman I, Gudayol-Ferr é E, Lira-Mandujano J, et al. Cognitive predictors of treatment response to bupropion and cognitive effects of bupropion in p atients with major depressive disorder. Psychiatry Res. 2008;160:72-82.
33. Herrera-Guzman I, Gudayol-Ferr é E, Herrera-Abarca JE, et al. Major depressive disorder in recovery and neuropsychologic al functioning: effects of selective serotonin reuptake inhibitor and dual inhibitor depression treatments on residual cognitive deficits in patients with major depressive disorder in recovery. J Affect Disord. 2010;123:341-350.
34. Ferguson JM, Wesnes KA, Schwartz GE. Reboxetine versus paroxetine versus placebo: effects on cognitive functioning in depressed patients. Int Clin Psychopharmacol. 2003;18:9-14.
35. Raskin J,Wiltse CG,Siegal A,et al., Efficacy of duloxetine on cognition, depression, and pain in elderly patients with major depressive disorder: an 8-week, double-blind, placebo-controlled trial, Am J Psychiatry., 2007, 164, 900-909.
36. Constant EL, Adam S, Gillain B, et al. Effects of sertraline on depressive symptoms and attentional and executive functions in major depression. Depress Anxiety. 2005; 21:78-89.
37. Gualtieri CT, Johnson LG. Bupropion normalizes cognitive performance in patients with depression. MedGenMed. 2007;9:22.
38. Culang-Reinlieb ME, Sneed JR, Keilp JG, et al. Change in cognitive functioning in depressed older adults following treatment with sertraline or nortriptyline. Int J Geriatr Psychiatry. 2012;27:777-784.
39. Katona C, Hans en T, Olsen CK. A randomized, double-blind, placebo-controlled, duloxetine-referenced, fixed-dose study comparing the efficacy and safety of LU AA21004 in elderly patients with major depressive disorder. Int Clin Psychopharmacol. 2012;27:215-223.